Inaqovi (Decitabine, Cedazuridine)

Decitabine inhibits DNA methyltransferase, leading to hypomethylation of DNA and re‑activation of tumor‑suppressor genes. Cedazuridine blocks the enzyme cytidine deaminase, which normally degrades decitabine, thereby increasing its oral bioavailability and allowing effective systemic exposure after a tablet is taken.

The prescribed dose of Inaqovi is determined by the treating physician based on the patient’s clinical condition, disease severity, and laboratory parameters. Dosing regimens are individualized and should follow the prescribing information provided by the healthcare professional.

The safety of Inaqovi in pregnancy or while breastfeeding has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and decisions should be made in consultation with a qualified healthcare provider.

To order Inaqovi, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any required temperature control) and import documentation.

Inaqovi offers an oral alternative to injectable hypomethylating agents, combining decitabine with cedazuridine to improve bioavailability. Compared with intravenous decitabine, it provides comparable efficacy with the convenience of oral administration, which can reduce clinic visits and improve patient quality of life.

Inaqovi tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children.

Inaqovi is taken orally as a tablet, usually once daily on a scheduled treatment cycle as directed by the prescribing physician. The tablet should be swallowed whole with water and not crushed or chewed.

Serious risks include severe infections due to bone‑marrow suppression, liver toxicity, pulmonary complications, tumor lysis syndrome, significant bleeding, and cardiac arrhythmias. Patients should be monitored closely for these events, and any signs of serious adverse reactions require immediate medical attention.

Inaqovi is contraindicated in patients with known hypersensitivity to decitabine, cedazuridine, or any tablet excipients. It should also be avoided in individuals with active uncontrolled infections or those receiving live vaccines, unless the benefits outweigh the risks as assessed by a healthcare professional.